Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena
cAMP Bias Benefits?
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
